SGC0946 is an inhibitor of the non-SET domain-containing methyltransferase DOT1L (IC50 = 0.3 nM).1 It is selective for DOT1L over a panel of 12 additional protein methyltransferases, DNA methyltransferase 1 (DNMT1), and a panel of 29 receptors and ion channels. SGC0946 reduces the levels of dimethylated lysine 79 on histone 3 (H3K79me2) in MCF-10A breast cancer cells (IC50 = 8.8 nM). It selectively reduces the viability of isolated human cord blood cells transformed with an MLL-AF9 fusion oncogene over those transformed with a TLS-ERG fusion oncogene when used at concentrations of 1 and 5 µM. Adoptive transfer of isolated human CD3+ T cells pre-incubated with SGC0946 (0.5 µM) prevents weight loss, increases survival, and reduces hepatic and colonic lymphocyte infiltration in a xenogeneic mouse model of graft versus host disease (GVHD).2WARNING This product is not for human or veterinary use.